CJC Without DAC: Names, Structures & Evidence

Understand why CJC without DAC and modified GRF(1–29) labels need careful interpretation before a paper is applied to a product.

Why the name can be confusing

CJC-1295 without DAC is a label used in research catalogs, often alongside modified GRF(1–29). These labels should prompt a request for structural documentation rather than an assumption that they describe exactly the same molecule in every catalog.

The original CJC-1295 development work focused on albumin-binding GHRH analogues. Removing or omitting that feature changes the chemical design relevant to the long-acting evidence. The paper is useful for understanding that distinction, not for authenticating a separate no-DAC preparation. ^[1]

What can and cannot be carried across

A GHRH analogue may be investigated for receptor activation, but receptor-family membership alone does not establish a shared half-life, potency or clinical effect. Those properties require evidence for the actual molecule.

Descriptions sometimes borrow results from a long-acting CJC-1295 trial and apply them to a short-acting catalog item. Before accepting that comparison, identify the sequence, modifications and study formulation. Evidence should follow the structure rather than the sales shorthand.

How to evaluate a sample description

Look for a complete sequence, terminal modifications and an explanation of whether an albumin-binding group is present. Analytical mass should be interpreted against that defined structure. A purity report cannot resolve an ambiguous target if the intended molecule itself is not specified.

For a biological experiment, record how exposure is controlled and how the response is sampled. A brief receptor response and a prolonged endocrine response are different observations even when both involve a related signaling pathway.

A careful reading avoids false precision

Statements about universally producing natural pulses or a fixed duration can exceed what a supplied name establishes. They should be tied to a specific experiment and a verified compound.

This guide addresses nomenclature and evidence matching. It does not establish equivalence with sermorelin, the original DAC-containing CJC-1295 or any clinical formulation, and it does not specify personal-use instructions.

Questions to bring to the evidence

• What exact structure is intended by the no-DAC label?
• Does the referenced study use that same structure?

Sources & further reading

1. Jetté et al. (2005): albumin-binding CJC-1295 researchPrimary preclinical study